5. Tarlock K, Alonzo TA, Gerbing RB, Raimondi SC, Hirsch BA, Sung L, et al. Gemtuzumab Ozogamicin Reduces
Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children’s Oncology Group. Clin Cancer Res Off J Am
Assoc Cancer Res. 2016 Apr 15;22(8):1951–7.
6. Tarlock K, Alonzo TA, Wang Y-C, Gerbing RB, Ries R, Loken MR, et al. Functional Properties of KIT Mutations Are
Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia. Clin
Cancer Res Off J Am Assoc Cancer Res. 2019 Aug 15;25(16):5038–48.
7. Schlenk RF, Paschka P, Krzykalla J, Weber D, Kapp-Schwoerer S, Gaidzik VI, et al. Gemtuzumab Ozogamicin in
NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study. J
Clin Oncol Off J Am Soc Clin Oncol. 2019 Dec 18;JCO1901406.
8. Fournier E, Duployez N, Ducourneau B, Raffoux E, Turlure P, Caillot D, et al. Mutational profile and benefit of
gemtuzumab ozogamicin in acute myeloid leukemia patients treated in the ALFA0701 trial. Blood. 2019 Dec 27;